Numinus Wellness

Numinus Wellness is a Canadian mental health company pioneering the clinical and scientific advancement of psychedelic-assisted therapies. Operating a network of clinics across Canada, Numinus delivers ketamine-assisted therapy and psychedelic-assisted psychotherapy directly to patients, integrating evidence-based protocols with compassionate clinical care. The company also holds a Health Canada license to conduct psychedelic research and produce controlled substances, enabling it to operate across the full continuum from compound development to patient treatment. This dual mandate positions Numinus as both a healthcare provider and a drug development platform within the emerging psychedelic medicine ecosystem.

Listed on the Toronto Stock Exchange under the ticker NUMI, Numinus has established itself as one of Canada's most recognized publicly traded companies in the psychedelic health space. The company has built meaningful infrastructure by combining patient-facing clinic operations with a federally licensed research facility, a combination that remains rare in the industry. Numinus has pursued clinical collaborations and research partnerships to generate real-world evidence supporting the efficacy and safety of psychedelic treatments. These milestones reflect a deliberate strategy to advance the field while building a scalable, compliant business model suited to the regulatory realities of psychedelic medicine.

Numinus represents a critical bridge between emerging neuroscience and accessible mental health care at a time when conventional treatments are failing large segments of the population. By operating regulated clinics alongside a licensed research and production facility, the company demonstrates that psychedelic therapies can be delivered responsibly within existing healthcare frameworks. For the broader neurotech and neuropharmacology industries, Numinus serves as a proof of concept that psychedelic medicine can achieve commercial viability without sacrificing scientific rigor or patient safety. Its work is helping to shape the regulatory, clinical, and operational standards that will define the future of the psychedelic therapeutics sector.